Swiss pharmaceutical giant seeks to bolster pipeline
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
https://www.wsj.com/health/pharma/roche-to-buy-telavant-from-roivant-sciences-and-pfizer-in-7-25-bln-deal-638ccc3cRoche’s deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs.Roche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences, a company started by Republican presidential candidate Vivek Ramaswamy, and Pfizer in a deal worth more than $7 billion.
The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.This copy is for your personal, non-commercial use only.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Chevron, Hess, Roivant, Textainer, Microsoft, Alphabet, and More Stock Market MoversChevron will buy Hess in all-stock deal valued at $53 billion, Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease...
Les mer »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Les mer »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Les mer »
Roche to Buy Telavant from Roivant Sciences, Pfizer for $7.1 BillionIt will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.
Les mer »
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Bln -- UpdateBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss...
Les mer »
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln DealBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it...
Les mer »